Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Bristol-Myers Squibb Company ( BMY) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Bristol-Myers Squibb Company rose 48 cents (1.3%) to $38.96 on average volume. Throughout the day, 12.8 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.2 million shares. The stock ranged in a price between $38.26-$38.98 after having opened the day at $38.47 as compared to the previous trading day's close of $38.48. Other companies within the Drugs industry that increased today were: Progenics Pharmaceuticals ( PGNX), up 29%, Aoxing Pharmaceutical Company ( AXN), up 12%, Atossa Genetics ( ATOS), up 11.1%, and Idera Pharmaceuticals ( IDRA), up 10.9%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $63.02 billion and is part of the health care sector. The company has a P/E ratio of 33.2, above the S&P 500 P/E ratio of 17.7. Shares are up 18.1% year to date as of the close of trading on Thursday. Currently there are seven analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and 13 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, solid stock price performance, growth in earnings per share, largely solid financial position with reasonable debt levels by most measures and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Supernus Pharmaceuticals ( SUPN), down 19.7%, Albany Molecular Research ( AMRI), down 12.9%, ARCA biopharma ( ABIO), down 10.3%, and Geron Corporation ( GERN), down 9.6%, were all laggards within the drugs industry with Gilead ( GILD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE.
null

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact